Oncotype DX Breast Recurrence Score ®: A Review of Its Use in Early-Stage Breast Cancer - PubMed

Oncotype DX Breast Recurrence Score ®: A Review of Its Use in Early-Stage Breast Cancer - PubMed

Oncotype DX Breast Recurrence Score ®: A Review of Its Use in Early-Stage Breast Cancer

Yahiya Y Syed 1

Affiliations 

• PMID: 32613290
 
• DOI: 10.1007/s40291-020-00482-7

Abstract

Oncotype DX Breast Recurrence Score® is a 21-gene prognostic and predictive assay indicated for use in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, lymph node (LN)-negative or up to three LN-positive, early-stage breast cancer. The assay is used worldwide and is conducted at a CLIA-certified central laboratory in the USA. The 21-gene assay generates a Recurrence Score for each tumour sample, based on expression levels of 16 breast cancer-related genes, normalized to five reference genes. The Recurrence Score is a continuous variable that provides an individualized estimate of 9-year distant recurrence risk and the likelihood of adjuvant chemotherapy benefit. The 21-gene Recurrence Score assay is extensively validated in clinical studies, which are well supported by real-world registry studies. The assay informs treatment decisions and reduces adjuvant chemotherapy use in routine clinical practices, and is estimated to be cost-effective. The 21-gene Recurrence Score assay is included in all major international treatment guidelines. Currently, it is the only multigene assay validated for prediction of chemotherapy benefit, as well as for prognosis.

Similar articles

• Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.

  Medical Advisory Secretariat.Ont Health Technol Assess Ser. 2010;10(23):1-57. Epub 2010 Dec 1.PMID: 23074401 Free PMC article.
• Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.

  Harnan S, Tappenden P, Cooper K, Stevens J, Bessey A, Rafia R, Ward S, Wong R, Stein RC, Brown J.Health Technol Assess. 2019 Jun;23(30):1-328. doi: 10.3310/hta23300.PMID: 31264581 Free PMC article.
• Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX® Breast Recurrence Score Assay.

  Curtit E, Mansi L, Maisonnette-Escot Y, Sautière JL, Pivot X.Eur J Surg Oncol. 2017 May;43(5):921-930. doi: 10.1016/j.ejso.2016.11.016. Epub 2016 Dec 14.PMID: 28087099 Review.
• Spotlight on the utility of the Oncotype DX® breast cancer assay.

  Siow ZR, De Boer RH, Lindeman GJ, Mann GB.Int J Womens Health. 2018 Feb 21;10:89-100. doi: 10.2147/IJWH.S124520. eCollection 2018.PMID: 29503586 Free PMC article. Review.
• The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center.

  Thibodeau S, Voutsadakis IA.Eur J Breast Health. 2019 Jul 1;15(3):163-170. doi: 10.5152/ejbh.2019.4901. eCollection 2019 Jul.PMID: 31312792 Free PMC article.